JP7332157B2 - アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 - Google Patents

アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 Download PDF

Info

Publication number
JP7332157B2
JP7332157B2 JP2019540076A JP2019540076A JP7332157B2 JP 7332157 B2 JP7332157 B2 JP 7332157B2 JP 2019540076 A JP2019540076 A JP 2019540076A JP 2019540076 A JP2019540076 A JP 2019540076A JP 7332157 B2 JP7332157 B2 JP 7332157B2
Authority
JP
Japan
Prior art keywords
ace2
amino acid
angiotensin
variant
renal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019540076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020506693A (ja
JP2020506693A5 (cg-RX-API-DMAC7.html
Inventor
バトル ダニエル
ワイソッキー ジャン
Original Assignee
ノースウェスタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースウェスタン ユニバーシティ filed Critical ノースウェスタン ユニバーシティ
Publication of JP2020506693A publication Critical patent/JP2020506693A/ja
Publication of JP2020506693A5 publication Critical patent/JP2020506693A5/ja
Priority to JP2023127196A priority Critical patent/JP2023133564A/ja
Application granted granted Critical
Publication of JP7332157B2 publication Critical patent/JP7332157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
JP2019540076A 2017-01-24 2018-01-24 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体 Active JP7332157B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023127196A JP2023133564A (ja) 2017-01-24 2023-08-03 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762449857P 2017-01-24 2017-01-24
US62/449,857 2017-01-24
PCT/US2018/014991 WO2018140456A1 (en) 2017-01-24 2018-01-24 Active low molecular weight variants of angiotensin converting enzyme 2 (ace2)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023127196A Division JP2023133564A (ja) 2017-01-24 2023-08-03 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Publications (3)

Publication Number Publication Date
JP2020506693A JP2020506693A (ja) 2020-03-05
JP2020506693A5 JP2020506693A5 (cg-RX-API-DMAC7.html) 2021-03-11
JP7332157B2 true JP7332157B2 (ja) 2023-08-23

Family

ID=62979214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019540076A Active JP7332157B2 (ja) 2017-01-24 2018-01-24 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
JP2023127196A Pending JP2023133564A (ja) 2017-01-24 2023-08-03 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023127196A Pending JP2023133564A (ja) 2017-01-24 2023-08-03 アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体

Country Status (4)

Country Link
US (4) US10443049B2 (cg-RX-API-DMAC7.html)
EP (1) EP3574094A4 (cg-RX-API-DMAC7.html)
JP (2) JP7332157B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018140456A1 (cg-RX-API-DMAC7.html)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
AU2018376565B2 (en) 2017-11-29 2024-10-31 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Methods for modulating pigmentation by angiotensin-converting enzyme 2 modulation
JP7340372B2 (ja) * 2019-07-11 2023-09-07 浜松ホトニクス株式会社 光活性化アデニル酸シクラーゼ
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
BR112022014552A2 (pt) * 2020-01-23 2022-10-25 Avirus Inc Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante
US20210236583A1 (en) * 2020-02-03 2021-08-05 Yuntao Wu Targeting the renin-angiotensin system for treatment of environment-and pathogen-induced lung injury
TWI886211B (zh) * 2020-02-13 2025-06-11 美商西雅圖免疫公司 重組ace2-fc融合分子以及製造及使用彼等之方法
US20230250410A1 (en) * 2020-02-13 2023-08-10 Systimmune, Inc. Recombinant ace2-fc fusion molecules and methods of making and using thereof
TWI895357B (zh) * 2020-02-20 2025-09-01 理筱龍 人參皂甙ｍ１作為血管收縮素調節酶的調節劑及其在治療包括冠狀病毒引起的症狀之疾病或病徵的用途
CN111474363A (zh) * 2020-02-22 2020-07-31 安徽华培生物科技有限公司 一种新型冠状病毒检测方法
WO2021174107A2 (en) * 2020-02-26 2021-09-02 Northwestern University Soluble ace2 variants and uses therefor
EP4130047A4 (en) * 2020-02-27 2024-07-31 Huahui Health Ltd. SOLUBLE ACE2 AND FUSION PROTEIN AND THEIR USES
WO2021170113A1 (zh) * 2020-02-29 2021-09-02 南京金斯瑞生物科技有限公司 ACE-2-Fc融合蛋白治疗冠状病毒的方法
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2021183717A1 (en) 2020-03-11 2021-09-16 Nantcell, Inc. Proteinaceous therapeutics
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
JP2023517403A (ja) * 2020-03-21 2023-04-26 ラリクス・バイオサイエンス・リミテッド・ライアビリティ・カンパニー Ａｃｅ２および補体経路の二重特異性および三重特異性機能性分子ならびにその使用
WO2021195009A1 (en) * 2020-03-23 2021-09-30 Sapience Therapeutics, Inc. Peptide antagonists of ace2-binding proteins
CN113444710A (zh) * 2020-03-25 2021-09-28 上海英脉德医疗科技有限公司 ACE2-Fc融合蛋白及其用途
WO2021202456A1 (en) * 2020-03-30 2021-10-07 The Wistar Institute Of Anatomy And Biology Synthetic soluble receptor mimics and methods of use for treatment of covid-19
WO2021197501A1 (zh) * 2020-04-02 2021-10-07 创观（苏州）生物科技有限公司 病毒不易感动物
US20230203466A1 (en) * 2020-04-03 2023-06-29 Medgenome Inc. Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment
CN116033926A (zh) * 2020-04-03 2023-04-28 北卡罗来纳大学教堂山分校 针对ace2靶向病毒可用的结合蛋白
US20230158125A1 (en) * 2020-04-20 2023-05-25 Sorrento Therapeutics, Inc. Pulmonary Administration of ACE2 Polypeptides
WO2021237239A1 (en) * 2020-05-18 2021-11-25 Northwestern University Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye
US11773385B2 (en) * 2020-05-19 2023-10-03 Children's Medical Center Corporation High-affinity human ACE2 construct for use in diagnosing and treating coronaviruses
WO2021247675A1 (en) * 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
JP2023531368A (ja) * 2020-06-25 2023-07-24 グリックニック インコーポレイテッド Ａｃｅ２－ｆｃ融合タンパク質および使用方法
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
WO2022012688A1 (en) * 2020-07-17 2022-01-20 Shenzhen Bay Laboratory Ace2-ig fusion variants
KR102492081B1 (ko) * 2020-07-28 2023-01-26 재단법인대구경북과학기술원 코로나바이러스 감염증 covid-19 치료용 펩타이드 및 이의 용도
US20220041660A1 (en) * 2020-08-06 2022-02-10 University Of Delaware Compositions and methods for sequestering viral particles in respiratory tract
US20230287088A1 (en) * 2020-08-06 2023-09-14 BioNTech SE Binding agents for coronavirus s protein
WO2022035998A1 (en) * 2020-08-11 2022-02-17 City Of Hope Compositions and uses of sars-cov-2 targeted chimeric antigen receptor modified nk cells
EP4221745A4 (en) * 2020-10-01 2025-01-01 Sichuan Baili Pharmaceutical Co. Ltd. RECOMBINANT ACE2-FC FUSION MOLECULES AND METHODS FOR THE PREPARATION AND USE THEREOF
WO2022075667A1 (ko) * 2020-10-05 2022-04-14 한양대학교 산학협력단 안정화된 ace2 변이체, 이를 이용한 ace2-fc 융합단백질 및 covid-19 예방 또는 치료용 약학 조성물
EP4228697A4 (en) * 2020-10-16 2025-01-01 Invisishield Technologies Ltd. Compositions for preventing or treating viral and other microbial infections
WO2022108013A1 (ko) * 2020-11-20 2022-05-27 재단법인대구경북과학기술원 코로나바이러스 감염증 covid-19 치료제 단백질 ctp 알파, ctp 베타, ctp 감마, ctp 델타 및 이의 용도
TW202237178A (zh) 2020-11-23 2022-10-01 美商建南德克公司 調節宿主細胞表面與ｓａｒｓ—ｃｏｖ—２交互作用之方法
WO2022119380A1 (ko) * 2020-12-03 2022-06-09 주식회사 유틸렉스 신규한 ace2 변이체 및 그의 이용
EP4011387A1 (en) * 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
WO2022159433A1 (en) 2021-01-20 2022-07-28 Singh Biotechnology, Llc Therapeutics directed against coronavirus
KR20230136628A (ko) * 2021-01-26 2023-09-26 내셔날 리서치 카운실 오브 캐나다 Ace2-수용체 엑토도메인 융합 분자 및 이의 용도
WO2022165246A1 (en) * 2021-01-29 2022-08-04 The Trustees Of The University Of Pennsylvania Compositions and method of use of mutant ace2 decoy variants
JP7539479B2 (ja) * 2021-02-10 2024-08-23 シーチュアン バイリ ファーマスーティカル シーオー． エルティーディー． 組換えａｃｅ２－ｆｃ融合分子、その製造方法及びその使用
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
WO2022246041A2 (en) * 2021-05-20 2022-11-24 Achelois Biopharma, Inc. Compositions and methods for multivalent surface display on enveloped particles
CN113324933B (zh) * 2021-06-01 2022-07-26 浙江大学 一种检测血管紧张素转换酶的方法及其应用
WO2022271863A1 (en) * 2021-06-23 2022-12-29 Chan Zuckerberg Biohub, Inc. Coronavirus neutralizing compositions and associated methods
US20230181700A1 (en) * 2021-12-09 2023-06-15 Gliknik Inc. Ace2 fc fusion proteins and methods of use
WO2023201304A2 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions for preventing or treating coronavirus infections
CA3256034A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
EP4335870A1 (en) 2022-09-06 2024-03-13 NantCell, Inc. Peptide therapeutics against sars-cov-2 spike protein
CN116023509A (zh) * 2022-11-18 2023-04-28 中国药科大学 一种融合蛋白及其应用
DE202023100085U1 (de) 2023-01-09 2023-02-03 Sundararajan Gothandam Eine doppelte Blockade des Renin-Angiotensin-Systems zur Verringerung der frühen Veränderungen der diabetischen Retinopathie und Nephropathie

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508759A (ja) 2012-02-10 2015-03-23 タリックス ファーマシューティカルズ リミテッド 末梢血管疾患を処置するための組成物および方法
JP2015519345A (ja) 2012-05-25 2015-07-09 ヤンセン バイオテツク，インコーポレーテツド 非天然コンセンサスアルブミン結合ドメイン
JP2016504042A (ja) 2013-01-14 2016-02-12 アペイロン バイオロジックス アーゲー 改変ａｃｅ２ポリペプチド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540930A (en) 1983-09-12 1985-09-10 Wisconsin Alumni Research Foundation Plywheel-powered mobile X-ray apparatus
US5124154A (en) 1990-06-12 1992-06-23 Insite Vision Incorporated Aminosteroids for ophthalmic use
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
WO2002061131A2 (en) 2000-12-04 2002-08-08 Bristol-Myers Squibb Company Human single nucleotide polymorphisms
AT506258A1 (de) 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
CN104147611A (zh) * 2009-09-30 2014-11-19 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
CA2957211C (en) 2013-10-18 2022-07-05 Trustees Of The University Of Pennsylvania Oral delivery of angiotensin converting enzyme 2 (ace2) or angiotensin-(1-7) bioencapsulated in plant cells
JP7332157B2 (ja) 2017-01-24 2023-08-23 ノースウェスタン ユニバーシティ アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
WO2021174107A2 (en) 2020-02-26 2021-09-02 Northwestern University Soluble ace2 variants and uses therefor
WO2021237239A1 (en) 2020-05-18 2021-11-25 Northwestern University Active low molecular weight variant of angiotensin converting enzyme 2 (ace2) for the treatment of diseases and conditions of the eye

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015508759A (ja) 2012-02-10 2015-03-23 タリックス ファーマシューティカルズ リミテッド 末梢血管疾患を処置するための組成物および方法
JP2015519345A (ja) 2012-05-25 2015-07-09 ヤンセン バイオテツク，インコーポレーテツド 非天然コンセンサスアルブミン結合ドメイン
JP2016504042A (ja) 2013-01-14 2016-02-12 アペイロン バイオロジックス アーゲー 改変ａｃｅ２ポリペプチド

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANDERSEN, J.T., et al.，"Extending half-life by indirect targeting of the neonatal Fc receptor (FcRn) using a minimal albumin binding domain."，J. BIOL. CHEM.，2011年，Vol.286, No.7，pp.5234-5241，DOI: 10.1074/jbc.M110.164848
NILVEBRANT, J., et al.，"The albumin-binding domain as a scaffold for protein engineering."，COMPUT. STRUCT. BIOTECHNOL. J.，2013年，Vol.6, No.7，e201303009 (6 pages)，DOI: 10.5936/csbj.201303009
WYSOCKI, J., et al.，"Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy."，KIDNEY INTERNATIONAL，2017年，Vol.91，pp.1336-1346，10.1016/j.kint.2016.09.032
YING, T., et al.，"Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics."，J. BIOL. CHEM.，2013年，Vol.288, No.35，pp.25154-25164，DOI: 10.1074/jbc.M113.484154
ZHAO, S., et al.，"Extending the serum half-life of G-CSF via fusion with the domain III of human serum albumin."，BIOMED RES. INT.，2013年，Vol.2013，107238 (8 pages)，DOI: 10.1155/2013/107238

Also Published As

Publication number Publication date
US10443049B2 (en) 2019-10-15
EP3574094A1 (en) 2019-12-04
US20200181594A1 (en) 2020-06-11
EP3574094A4 (en) 2020-11-11
JP2020506693A (ja) 2020-03-05
US11078471B2 (en) 2021-08-03
US11891638B2 (en) 2024-02-06
WO2018140456A1 (en) 2018-08-02
US20220033794A1 (en) 2022-02-03
JP2023133564A (ja) 2023-09-22
US20180230447A1 (en) 2018-08-16
US20240392274A1 (en) 2024-11-28

Similar Documents

Publication Publication Date Title
JP7332157B2 (ja) アンジオテンシン変換酵素２（ａｃｅ２）の活性な低分子量変異体
US11358995B2 (en) Compositions and methods of use for treating metabolic disorders
US12123036B2 (en) Soluble ACE2 variants and uses therefor
JP6914193B2 (ja) Ｂｄｎｆを含む融合蛋白質
KR102569658B1 (ko) 컨쥬게이트 c1 에스테라제 억제제 및 그의 용도
JP2017509628A (ja) リポジストロフィーおよびインスリン産生の欠損またはインスリンシグナル伝達の欠損と関連する代謝性障害を処置する方法
US20240228585A1 (en) Fc-fusion protein therapeutic for the treatment of pancreatitis
AU2014233219B2 (en) Methods for treatment of nephrotic syndrome and related conditions
TW200529870A (en) Therapeutic use of factor XI
US20240262877A1 (en) Kidney active fusion proteins and methods of treatment using the same
WO2022251168A1 (en) Kidney active fusion proteins and methods of treatment using the same
JP5121400B2 (ja) 筋ジストロフィ治療薬
HK1237790B (en) Compositions and methods of use for treating metabolic disorders
NZ728101B2 (en) Compositions and methods of use for treating metabolic disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210125

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230704

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230803

R150 Certificate of patent or registration of utility model

Ref document number: 7332157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150